PVCT announced that it had a Type C meeting with the FDA on December 16. It is not allowed to disclose the content of the meeting until it gets the official minutes, within 30 days. Those who follow this stock expect that they were granted some sort of accelerated path to approval for its lead drug, pv-10. This drug has proven effective in stage III melanoma and it has no significant side effects. It is cheap to make and easy to store and transport. It has been shown effective for other solid tumors as well. The company has flown under the radar for a long time, but this seems to be ending. The risked, discounted value of approval is many times the current price.